Article
10 Sep 2026
“No Charter right to bicycle lanes”: Court of Appeal for Ontario reins in section 7 claim
AUTHORS CONTENT
Article
17 Aug 2026
Tariff-ic Timing? FCA Reinforces Limits On Early Judicial Review
Article
31 Jul 2026
Supreme Court Confirms: Judicial Review Cannot Be Legislated Away
Article
22 Jul 2026
Les schémas posologiques sont maintenus, mais la CSC confirme l’interdiction du Canada de breveter les méthodes de traitement médical
Article
21 Jul 2026
Dosing Regimens Survive But The SCC Keeps Canada’s Bar On Patenting Methods Of Medical Treatment
Article
01 Jul 2026
Speak Now or Forever Lose the Point: Federal Court of Appeal on Raising Issues Early Before Administrative Decision-Makers
Article
19 May 2026
Health Canada Removes Phase III Trials For Biosimilars: What It Means For Patent Enforcement
Article
18 May 2026
Same Defence, Better Facts: Federal Court Allows Amendments To Bolster Prior Use Allegation
Article
29 Dec 2025
Les lignes directrices définitives du CEPMB sur le prix des médicaments brevetés entrent en vigueur le 1er janvier 2026 : ce que cela signifie pour les entreprises pharmaceutiques innovantes
Article
23 Dec 2025
Final Patented Medicines Pricing Guidelines From The PMPRB Take Effect On January 1, 2026: What This Means For Innovative Pharma
Article
21 Nov 2025
Dealing A New Hand: Federal Court Gives Card Game Patent A Second Chance
Article
06 Nov 2025
Streamlined Biosimilar Approvals: What The End Of Biosimilar Phase III Trials Means For Innovative Pharmaceutical Patent Holders
Article
28 Oct 2025
What The Frack? FCA Clarifies Claim Construction And Double Patenting
Article
04 Aug 2025
Aperçu du rapport statistique 2024-2025 de Santé Canada sur le régime canadien des brevets pharmaceutiques
Article
31 Jul 2025
Insights From Health Canada's 2024–2025 Statistical Report On Canadian Pharmaceutical Patent Regime
Article
20 Jun 2025
Biosimilar Update: Health Canada Reconsiders Requirement For Comparative Clinical Trials
Article
23 Dec 2024
Novel Biosimilar Anti-Trust Complaint Involving Janssen's STELARA (Ustekinumab) Dismissed By The Canadian Competition Tribunal
Article
23 Dec 2024
Federal Court Of Appeal: No Single Or Mandatory Approach To Obviousness; Prior Art Disclosing Multiple Options Can Anticipate
Article
19 Dec 2024
Federal Court Of Appeal: Patented Medicine Prices Review Board "Crashed" Through "Guardrails" In Attempt To Regulate Unpatented Medicine
Article
05 Nov 2024
Appealing Briefs - Episode 12: Democracy Watch (Podcast)